SCHEMBL7048017

SCHEMBL7048017

CCOC(=O)C(CC1CCCCC1)(C[PH](=O)COS(=O)(=O)c1ccc(C)cc1)OCC

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP3 O14638 2/20 0.37
ENPP1 P22413 2/20 0.37
ENPP2 Q13822 2/20 0.37
ALDH1A1 P00352 4/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
LMNA P02545 2/20 0.35
MMP1 P03956 1/20 0.34
MMP9 P14780 1/20 0.34
MMP13 P45452 1/20 0.34
ADAM17 P78536 1/20 0.34
STAT3 P40763 2/20 0.34
POLB P06746 3/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
BMP1 P13497 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7238354 0.82 ALDH1A1 (0.37) ALDH1A1NPSR1L3MBTL1LMNASTAT3
SCHEMBL7052400 0.81 POLB (0.37) ENPP1ALDH1A1LMNASTAT3POLB
SCHEMBL7050906 0.80 ALDH1A1 (0.38) ALDH1A1NPSR1LMNASTAT3POLB
SCHEMBL7049019 0.78 METAP2 (0.33) ALDH1A1L3MBTL1
SCHEMBL7051779 0.77 FKBP1A (0.37) ALDH1A1LMNASTAT3POLBCNR2
SCHEMBL7051290 0.71 MAPT (0.38) ALDH1A1LMNAPOLBMAPTKMT2A
SCHEMBL7054025 0.70 ALDH1A1 (0.34) ALDH1A1NPSR1L3MBTL1LMNACNR1
SCHEMBL11090057 0.70 ENPP3 (0.45) ENPP3ENPP1ENPP2ALDH1A1MAPK1
SCHEMBL7049866 0.69 PRNP (0.45) ALDH1A1MAPK1NPSR1L3MBTL1LMNA
SCHEMBL7054000 0.67 ALDH1A1 (0.36) ALDH1A1NPSR1L3MBTL1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212067-A1 Matrix metalloprotease inhibitors CASTELHANO ARLINDO LUCAS (US) 2003-11-13 US disclosed
US-6579890-B1 Matrix metalloprotease inhibitors SYNTEX (U.S.A.) INC. 2003-06-17 US disclosed
US-6037472-A FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS SYNTEX (U.S.A.) INC. (US) 2000-03-14 US disclosed
EP-0793643-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1997-09-10 EP disclosed
EP-0726903-B1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX INC (US) 1997-07-16 EP disclosed
WO-1996016027-A1 MATRIX METALLOPROTEASE INHIBITORS SYNTEX (U.S.A.) INC. (US) 1996-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212067-A1 Matrix metalloprotease inhibitors MMP7, MMP1, MMP3 ENPP3 1488/4885ENPP1 466/4885ENPP2 607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.